“If you are chasing moves in this market, you’re an idiot. This is the market for ultimate fading.”
That was STN Chief Strategist Dennis Dick this morning, laying out the play after last night’s mega-cap tech reports. If you look at how earnings are being digested across the tape today, it’s easy to see why. Good news in big tech is being treated as a liquidity event to sell into, while institutional money rotates into M&A, healthcare, and cash-flowing industrials.
On paper, hyperscale cloud growth is still putting up monster numbers but the market wasn’t in a forgiving mood after the bell:
- Microsoft (NASDAQ: MSFT) — Beat, Pop, and Fade: Delivered a textbook Q1 beat with EPS of $4.89 (vs. $4.72 est.) and revenue of $92.30B (vs. $90.74B est.), powered by 48% Azure growth. As Dennis noted, “MSFT said nothing wrong in the call,” giving traders two or three post-close pops before sellers stepped in every time to offload tech exposure.
- Alphabet (NASDAQ: GOOG) — Cloud Doubles, Search Questions Loom: Dropped as much as 11.79% after-hours following a Q3 EPS miss ($2.12 vs. $2.97 est.) and slight top-line miss ($127.58B vs. $127.91B est.). Even with Google Cloud surging 103% YoY to $30.7B, the Street zeroed in on the long-term threat to its core cash cow.
“Nothing moves the engine like Search. This is serious—they have to learn how to monetize their own AI agents to replace the search revenue, because the search revenue is everything to Google,” Dennis said on Alphabet’s post-close slide.
If you step outside the mega-cap tech hangover into delivery M&A and Big Pharma, the tape is rewarding size and guidance hikes in a big way:
- DoorDash (NASDAQ: DASH) Locks Up Grocery: After an early halt, DoorDash officially agreed to take out Instacart (NASDAQ: CART) for $65/share in cash and stock. Even better for the bulls, DoorDash backed up the deal with a monster Q3 of its own, crushing EPS ($1.06 vs. $0.81 est.) as Marketplace GOV surged 36% to $33.9B.
- Big Pharma’s Beat-and-Raise Sweep: Healthcare is doing the heavy lifting this morning. Eli Lilly (NYSE: LLY) blew the doors off Q3 ($7.48 EPS vs. $6.61 est. on $24.4B in sales) and hiked its full-year revenue midpoint by $5.5B to the $91B–$92B range. Merck (NYSE: MRK) and Bristol Myers (NYSE: BMY) followed right behind with Q3 beats and full-year guidance raises of their own.
- Pockets of Strength in Consumer & Industrials: While homebuilder D.R. Horton (NYSE: DHI) whiffed on Q4 EPS and CRH (NYSE: CRH) leaned on a $6B buyback to soften a Q3 miss, plenty of old-economy names delivered. Crocs (NASDAQ: CROX), Altria (NYSE: MO), Norwegian Cruise Line (NYSE: NCLH), L3Harris (NYSE: LHX), Textron (NYSE: TXT), and BorgWarner (NYSE: BWA) all raised their full-year EPS outlooks, while Caterpillar (NYSE: CAT) and Mastercard (NYSE: MA) notched Q3 beats.
- Crypto Comes Onshore & PCE Stays Sticky: On the macro front, September Core PCE landed in line at 0.3% MoM (ticking up to 3.1% YoY), while personal spending cooled slightly to 0.5%. Meanwhile, institutional crypto took a step forward as NYSE-parent ICE (NYSE: ICE) beat Q3 estimates and announced plans to bring Hyperliquid perpetual futures onshore to the U.S. (sending NASDAQ: PURR up $2), Canton Strategic (NASDAQ: CNTN) moved to become the first tokenized U.S. equity, and Galaxy Digital (NASDAQ: GLXY) applied for a National Trust Bank charter.
“INTC, AMZN, SNDK—these are going to be huge market movers. Amazon first,” Dennis said of tonight’s post-close slate.
STN Desk Takeaway: Don’t chase the first headline rip, especially in tech, where clean numbers are getting faded by trapped longs looking for liquidity. Let the morning dust settle around the DASH/CART arb spread and Big Pharma strength.
